Sarah Schwartz
Baxter
a,
Christopher F.
Dibble
b,
Warren C.
Byrd
c,
Jim
Carlson
a,
Charles Russell
Mack
c,
Ivandario
Saldarriaga
c and
Sompop
Bencharit‡
*bc
aDavid H. Murdock Research Institute, North Carolina Research Campus, Kannapolis, NC 28081, USA
bDepartment of Pharmacology, School of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA
cDepartment of Prosthodontics and the Dental Research Center, School of Dentistry, University of North Carolina, Chapel Hill, NC 27599, USA
First published on 17th April 2014
Three genetic mutations were found to cause cerebral cavernous malformation (CCM), a vascular anomaly predisposing affected individuals to hemorrhagic stroke. These CCM proteins function together as a protein complex in the cell. Loss of expression of each CCM gene results in loss of in vitro endothelial tube formation. Label-free differential protein expression analysis using multidimensional liquid chromatography/tandem mass spectrometry (2D-LC-MS/MS) was applied to explore the proteomic profile for loss of each CCM gene expression in mouse endothelial stem cells (MEES) compared to mock shRNA and no shRNA control cell-lines. Differentially expressed proteins were identified (p < 0.05). 120 proteins were differentially expressed among the cell-lines. Principal component analysis and cluster analysis show the effects of individual knockdown. In all knockdown cell-lines, altered expression of cytoskeletal proteins is the most common. While all CCM mutations result in similar pathology, different CCM mutations have their own distinct pathogenesis in cell signaling.
Three CCM loci have been mapped in humans: 7q21-22 (CCM1), 7p13-15 (CCM2), and 3q25.2-27 (CCM3). Mutations in these CCM loci (e.g. frameshift, nonsense, splice-site, missense, and multi-exon deletions) cause loss of function of these proteins and result in CCM.8–13 The genes for CCM1, CCM2, and CCM3 encode Krit1 (krev interaction trapped 1), OSM (osmosensing scaffold for MEKK3) or malcaverin, and PDCD10 (programmed cell death 10), respectively. The mode of inheritance for congenital CCM is autosomal dominant. Although haplo-insufficiency is one model to explain the genetic basis of CCM, there is evidence that a Knudson-like two-hit mechanism may initiate lesion development.14
Krit1 or CCM1 protein was first described as a binder of krev-1 or rap1A, an evolutionary conserved Ras-family GTPase.15–17 Krit1 is composed of three domains, including an unstructured N-terminal domain containing three NPXY motifs, three ankyrin repeats (ANK), and a C-terminal Four-point one, Ezrin, Radixin, Moesin (FERM) domain. NPXY motifs are usually recognized by phosphotyrosine binding (PTB) domains and play an important role in protein–protein interactions.3,18,19 Both ankyrin repeats and FERM domains typically interact with actin.18 Krit1, a scaffold with no known catalytic activity, may function through its interaction with rap1A and the NPXY–PTB interactions with CCM2 protein (OSM) and Icap1 (integrin cytoplasmic domain associated protein). Icap1 is a 200 amino acid scaffolding protein encoding a PTB domain. Icap1 is known to bind small GTPases including Rac1 and Cdc42. Icap1 also interacts with the cytoplasmic domain of β1-integrin and participates in integrin-mediated signaling.17–20 The N-terminal portion of Krit1 also interacts with SNX17, a phosphatidylinositol-3,4,5-trisphosphate (PtdIns(3,4,5)P3) binding protein.20
OSM or CCM2 protein is composed of an N-terminal PTB domain (∼200 amino acids) and a C-terminal domain (∼300 amino acids) with no other recognizable structural motif. OSM was first described as a scaffolding protein that binds distinct kinases including MKK3 and MEKK3, as well as Rac1, and actin to coordinate the activation of the p38 MAPK cascade in response to hyperosmolarity.21 Our previous evolutionary studies show that the PTB domain of OSM has the closest relation to the PTB domain of Icap1.22 It is possible that OSM and Icap1 competitively interacts with the NPXY motifs in the N-terminal region of Krit1.14,16–21,23 OSM was first functionally identified as a scaffold protein that facilitates the activation of the MEKK3-MKK3-p38 MAPK cascade at sites of actin reorganization.23 OSM is localized, in part, to the actin cytoskeleton, and binds the small GTPase Rac1, the MAP3 kinase-MEKK3, and the MAP2 kinase-MKK3, an activator of p38. During osmotic stress, the MEKK3–OSM complex is recruited to membrane ruffles and both MEKK3 and the p38 stress-activated protein kinase are activated.23,24 A signaling complex of Krit1–OSM links the p38 activation of OSM with integrin-signaling through Krit1–Icap1 interaction.24–26 Additionally, we showed that the PTB domain of OSM binds the ubiquitin ligase (E3) Smurf1 which controls RhoA degradation and CCM2 knockdown phenotype can be recovered by overexpression of RhoA or inhibition of ROCK in endothelial cell culture.27,28
PDCD10 or CCM3 protein is a 25 KDa protein composed of only 212 amino acids. It was originally identified as TF-1 cell apoptosis related gene-15 (TFAR15), since it is up-regulated with the induction of apoptosis by serum withdrawal in TF-1 human premyeloid cells.8,12 It was subsequently renamed PDCD10 (programmed cell death 10 gene) as it was thought to be involved in apoptotic responses.8,12 PDCD10 is the third and the latest CCM gene identified.8,12,29–31 The N-terminal region of PDCD10, the site of L33-K50 deletion mutations in some CCM patients, was found to be the binding site for the oxidant stress response serine/threonine kinase 25 (STK25) and the mammalian Ste20-like kinase 4 (MST4).26 Similar to earlier observation of PDCD10, PDCD10 may function in apoptotic pathways since overexpression of wild-type PDCD10 induces apoptosis through caspase 3 pathway.29 PDCD10 may be regulated through phosphorylation and dephosphorylation, since it can be phosphorylated by STK25 and dephosphorylated by binding to the phosphatase domain of Fas-associated phosphatase-1.26 PDCD10 binds directly to OSM,31 and the PDCD10–OSM interaction is independent of the OSM–Krit1 interaction.29,31 We recently showed that PDCD10 binds specifically to PtdIns(3,4,5)P3 and the C-terminal amphipathic helix is responsible for PDCD10's function through its interaction with PtdIns(3,4,5)P3 and OSM. In addition, we previously proposed that PDCD10 may function in concerts with phosphoinositol-3 kinase (PI3K), the most important enzymes in the regulation of PtdIns(3,4,5)P3 at the plasma membrane.31
It is clear that all three CCM proteins function together and form complex in cell.26,31 In addition, individual knockdown of each CCM gene has been used as a tool to understand the function of each protein.26,31 However, while specific signaling pathways were revealed through studies of loss of CCM gene expression, the global proteomic changes resulting from these knockdowns are not known. Comparing the proteomic change resulting from individual CCM knockdown would reveal not only the common expressed proteins, but may also allow insight into novel signaling pathways related to each individual CCM gene. In this study, we examined the proteomic effects of loss of CCM gene expression in mouse endothelial embryonic stem cell (MEES) using label-free quantitative proteomic approach. Our analysis suggests that each CCM knockdown cell-line produces unique proteomic profiles corresponding to endothelial function phenotypes, and signaling proteins involved in cytoskeletal development are among the most common proteins in CCM knockdown cell-lines. The results suggest that proteomic analysis may be used as a tool to examine CCM related signaling pathways in future CCM studies.
To examine the global changes of each CCM knockdown, a label-free differential expression LC/MS/MS method was used to quantitatively compare the protein expression among all five cell lines; three CCM knockdown cell lines and two control cell lines (Fig. 1A–E). The total protein in each sample was calibrated (Fig. 2A and B). MS data from all five cell lines were analyzed in triplicate (15 replicates). Data processing in Elucidator was performed in multiple steps that included mass correction and mass signal alignment of detected signals, retention time alignment of detected signals, and feature selection, with features representing mass signals detected within the study set. QC review of the aligned data indicated the mass signals were correctly aligned in the Elucidator software (Fig. 2A and B). For retention time alignment, mathematical adjustments are performed to time-align the same detected signals across all samples. QC assessment of this retention time shift indicates that all adjustments were <3 min. Principal component analysis (PCA) was performed on the collected data set to evaluate the data for outliers (Fig. 2C and D) and sample trends. Results from the unsupervised analysis suggest that the samples differentiate by cell line based on the mass spectrometric patterns detected.
Fig. 2 Mass Spectrometry Analysis (A–B). Aligned Mass Data. An example of aligned peptide signals for the data set is presented. Sample labels: figures are color coded according to cell line. Selection (red) references an option to manually select a single sample to be highlighted. This option was not selected. (A) Extracted ion chromatogram for m/z 633.0408–633.7484 from retention time 548391–556203 demonstrates retention time alignment across all samples for this signal. (B) Aligned masses in the mass range of 633.0408–633.7484 for all samples in the study set. (C). PCA plot for the study set. An ANOVA test was performed using all mass signals detected to compare the expression results from the five cell lines. Results demonstrate an unsupervised separation of the five cell lines based on the mass signal patterns. (D). PCA for cell line replicates. An ANOVA test was performed at the protein level to compare the protein expression results from the five cell lines. Candidate differentially expressed proteins were determined and are presented in the ESI,† Table S1. Results demonstrate separation of the five cell lines based on the protein patterns determined based on an ANOVA test. (E). Cell line cluster based on differentially expressed proteins determined by ANOVA. |
Comparing all five cell lines, the mass spectrometry analytical results were processed using the Rosetta Elucidator software. When applicable, mass signals were annotated with the corresponding peptide and protein information based on the database search results using a 1% false discovery rate cutoff. Data processing of the Thermo Orbitrap data resulted in detection of 177590 features (mass signals). Of these, 3925 were annotated with peptide information that corresponded to the identification of 689 peptides corresponding to 258 proteins. PCA demonstrates a clear distinct proteomic profile for each cell line (Fig. 2C). We then compared all cell lines using an error-weighted ANOVA to determine mass patterns that correlated to differentially expressed proteins between the cell lines. Signals with a p < 0.01 were selected as tentative markers and summarized by protein. Total of 122 proteins are differentially expressed among three cell line samples. One hundred and ten proteins are differentially expressed among the three CCM knockdown cell lines. PCA again shows clear proteomic distinction of each cell line (Fig. 2D). Cluster heat maps based on these protein expression patterns, and the corresponding tentative differentially expressed signals are presented in Fig. 2E and ESI,† Table S1.
Gene/sequence ID
Protein description |
Condition(s) with highest expression | Function | Subunits |
---|---|---|---|
a Cytoskeletal proteins. b Proteins associated with CCM protein complex (Hilder et al. 2007). | |||
EF1A1/P10126b
Elongation factor 1-alpha 1 |
Cell line 1, cell line 2 | Enhances the binding of amino-acyl tRNA to the ribosome A-site, a GTP-dependent process | Binds to CCM protein complex |
EF1G/Q9D8N0
Elongation factor 1-gamma |
Cell line 1, cell line 2, cell line 3 | Probably plays a role in anchoring the complex to other cellular components | EF-1 is composed of four subunits: alpha, beta, delta, and gamma |
TCPB/P80314a,b
T-complex protein 1 subunit beta |
Cell line 1, cell line 2, cell line 3 | Serves as a molecular chaperone by assisting the folding of proteins upon ATP hydrolysis. Known to help in folding of actin and tubulin, in vitro | Exists as heterooligomeric complex (850 to 900 kDa) which forms two stacked rings |
TCPG/P80318a,b
T-complex protein 1 subunit gamma |
Cell line 1, cell line 2, cell line 3 | Serves as a molecular chaperone by assisting the folding of proteins upon ATP hydrolysis. Known to help in folding of actin and tubulin, in vitro. Plays a part in the assembly of the von Hippel–Lindau ubiquitination complex | Exists as heterooligomeric complex (850 to 900 kDa) which forms two stacked rings |
TAGL/P37804a
Transgelin |
Cell line 1, cell line 2, cell line 4 | Functions in actin cross-linking/gelling protein | |
ENOA/P17182b
Enolase |
Cell line 1, cell line 2, cell line 3 | Multifunctional enzyme that, as well as its role in glycolysis, plays a part in various processes such as growth control, hypoxia tolerance and allergic responses. By similarity. May also function in the intravascular and pericellular fibrinolytic system due to its ability to serve as a receptor and activator of plasminogen on the cell surface of several cell-types such as leukocytes and neurons. Stimulates immunoglobulin production | Mammalian enolase is composed of 3 isozyme subunits, alpha, beta and gamma, which can form homodimers or heterodimers which are cell-type and development-specific. ENO1 interacts with PLG in the neuronal plasma membrane and promotes its activation. The C-terminal lysine is required for this binding by similarity. In vitro, interacts with several glycolytic enzymes including PKM2, PGM, CKM and aldolase. Also binds troponin, in vitro. |
GBLP/P68040b
Guanine nucleotide-binding protein subunit beta-2-like 1 |
Cell line 1, cell line 2, cell line 3 | Involved in the recruitment, assembly and/or regulation of a variety of signaling molecules. Interacts with a wide variety of proteins and plays a role in many cellular processes. Component of the 40S ribosomal subunit involved in translational repression. Binds to and stabilizes activated protein kinase C (PKC), increasing PKC-mediated phosphorylation. May recruit activated PKC to the ribosome, leading to phosphorylation of EIF6. Inhibits the activity of SRC kinases including SRC, LCK and YES1. Inhibits cell growth by prolonging the G0/G1 phase of the cell cycle. Enhances phosphorylation of BMAL1 by PRKCA and inhibits transcriptional activity of the BMAL1-CLOCK heterodimer. Facilitates ligand-independent nuclear translocation of AR following PKC activation, represses AR transactivation activity and is required for phosphorylation of AR by SRC. Modulates IGF1R-dependent integrin signaling and promotes cell spreading and contact with the extracellular matrix. Involved in PKC-dependent translocation of ADAM12 to the cell membrane. Promotes the ubiquitination and proteasome-mediated degradation of proteins such as CLEC1B and HIF1A. Required for VANGL2 membrane localization, inhibits Wnt signaling, and regulates cellular polarization and oriented cell division during gastrulation. Required for PTK2 phosphorylation and dephosphorylation. Regulates internalization of the muscarinic receptor CHRM2. Promotes apoptosis by increasing oligomerization of BAX and disrupting the interaction of BAX with the anti-apoptotic factor BCL2L. Inhibits TRPM6 channel activity. Regulates cell surface expression of some GPCRs such as TBXA2R. Plays a role in regulation of FLT1-mediated cell migration. | Component of the small (40S) ribosomal subunit. Exists as a monomer and also forms oligomers. Binds SLC9A3R1. Forms a ternary complex with TRIM63 and PRKCE. Interacts with HABP4, KRT1 and OTUB1. Interacts with SRC (via SH2 domain); the interaction is enhanced by tyrosine phosphorylation of GNB2L1/RACK1. Recruited in a circadian manner into a nuclear complex which also includes BMAL1 and PRKCA. Interacts with AR. Interacts with IGF1R but not with INSR. Interacts with ADAM12. Interacts with CLEC1B (via N-terminal region) and with HIF1A; the interaction promotes their degradation. Interacts with RHOA; this enhances RHOA activation and promotes cell migration. Interacts with CHRM2; the interaction regulates CHRM2 internalization. Interacts with TRPM6 (via kinase domain). Interacts with PTK2; required for PTK2 phosphorylation and dephosphorylation. Interacts with FLT1. |
MYH9/Q8VDD5a
Myosin-9 |
Cell line 1, cell line 3 | Plays a role in cytokinesis, cell shape, and specialized functions such as secretion and capping | Exists as a hexamer consisting of 2 heavy chain subunits (MHC), 2 alkali light chain subunits (MLC) and 2 regulatory light chain subunits (MLC-2) |
TBA1A/P68369a,b
Tubulin alpha-1A chain |
Cell line 1, cell line 2, cell line 3 | Serves as the major constituent of microtubules. It binds two moles of GTP, one located on an exchangeable site on the beta chain and the other at a non-exchangeable site on the alpha chain | Exists as a dimer of alpha and beta chains |
TBA1B/P05213a,b
Tubulin alpha-1B chain |
Cell line 1, cell line 2, cell line 3 | Serves as the major constituent of microtubules. It binds two moles of GTP, one located on an exchangeable site on the beta chain and the other at a non-exchangeable site on the alpha chain | Exists as a dimer of alpha and beta chains |
TBB5/P99024a,b
Tubulin beta-5 chain |
Cell line 1, cell line 2, cell line 3 | Serves as the major constituent of microtubules. It binds two moles of GTP, one located on an exchangeable site on the beta chain and the other at a non-exchangeable site on the alpha chain | Exists as a dimer of alpha and beta chains |
Top canonical pathways | ||
---|---|---|
p-value | Ratio | |
Protein ubiquitination
pathways |
3.48 × 10−07 | 7/64 |
ElF2 signaling | 4.87 × 10−07 | 7/70 |
Aldosterone signaling in epithelial cells | 1.12 × 10−05 | 6/71 |
Actin cytoskeleton signaling | 2.14 × 10−05 | 7/126 |
eNOS signaling | 4.11 × 10−05 | 6/87 |
The proteomic alteration of cytoskeletal proteins, actin and tubulin isoforms, may be a result of loss of protein complex stability from missing CCM protein interaction. Microtubule stabilization through tubulin–protein interaction is known to regulate the cell polarization and proliferation. For instance, RASSF1A Tumor Suppressor is shown to be involved in the control of microtubule polymerization and in the maintenance of genomic stability.27 This may be similar to CCM complex stabilizing tubulin polymerization through their direct interaction. CCM proteins, e.g. Krit1 and OSM, are also known to interact with actin17,23 and, perhaps stabilize the actin–tubulin complex through their interactions with cofilin and profilin34 (Fig. 4). Cofilin, regulated by LIM-kinase 1,34 controls actin polymerization.35 Cofilin, known as actin-depolymerizing factors, functions with Arp2/3 complex in the opposite direction of profilin to control actin polymerization.36,37 Our proteomic results are inconclusive as to whether cofilin and profilin are differentially expressed among the knockdown, WT, and mock groups. (ESI,† Fig. S1) The relative fold expression of the groups for cofilin and profilin were included as a figure due to previous evidence for the proteins' involvement in the development of the CCM.38
Footnotes |
† Electronic supplementary information (ESI) available. See DOI: 10.1039/c3mb70199a |
‡ Department of Prosthodontics, School of Dentistry; and Department of Pharmacology, School of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA. E-mail: E-mail: Sompop_Bencharit@dentistry.unc.edu |
This journal is © The Royal Society of Chemistry 2014 |